Browsing Tag

CoVepiT

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its…

Eli Pacheco Mar 16, 2022 0

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.CoVepiT, based on 13 peptides, elicits durable T-cell…

Health

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical…

Eli Pacheco Nov 30, 2021 0

New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy volunteers vaccinated.Promising preclinical efficacy signals guide development in…

Health

OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1…

Eli Pacheco Jul 19, 2021 0

NANTES, France, July 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced a voluntary and temporary pause of enrollment and dosing in…

Health

OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical…

Eli Pacheco Jun 30, 2021 0

NANTES, France and FONTENAY-SOUS-BOIS, France, June 30, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Cenexi, a French contract development and…